Cultivates cannabis plants. Manufactures cannabis products, including flower, pre-rolls, concentrates, and edibles. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
The gap is $243.1M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 13.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Analysts' average target sits 148% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 74% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 32 buys and 16 sells. Management buying with its own money is usually read as a good sign.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.